Using Fibroscan to guide lower anti-rejection medicine after liver transplant
Part of Immune system & allergy clinical trials.
This trial uses a special ultrasound (Fibroscan) to check your liver health and see if you can safely reduce your anti-rejection medications. It is for people who are at least 2 years past a liver transplant and whose liver is working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a liver transplant at least 2 years ago
- You are 18 years or older
- No rejection episode in the last 12 months
- Your liver enzymes (ALT and bilirubin) are normal
- You did not have a transplant for an autoimmune liver disease
- You are not more than 6 years past your transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether children who had a liver transplant before age 6 can safely stop taking their anti-rejection medicine. It's for children who are doing well — with normal liver function and no signs of rejection or scarring — at least 4 years after transplant.
This study uses a special ultrasound (Fibroscan) to check how well immunotherapy is working for advanced liver cancer. It may help doctors see if the treatment is effective without needing a biopsy.
This trial compares two ways to check the health of a liver before donation: a traditional liver biopsy versus a non-invasive scan called FibroScan with CAP. The goal is to see if the scan can replace the biopsy for donor evaluation.
This study tests whether long-term liver transplant recipients (5+ years after transplant) can safely stop or reduce their immunosuppressant medications by checking for donor cells (chimerism) in the liver. If you have stable liver function and agree to a liver biopsy, you may be able to join.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.